Wild type KRAS

About

Gene context: KRAS

Biomarker Type: Wild type

Present: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (2) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
FDA (1) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib